Market Research Report
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H2 2018
|Published by||Global Markets Direct||Product code||516035|
|Published||Content info||44 Pages
Delivery time: 1-2 business days
|Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H2 2018|
|Published: November 20, 2018||Content info: 44 Pages||
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report Apoptosis Regulator BAX - Pipeline Review, H2 2018, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions. The molecules developed by companies in Phase II and Preclinical stages are 1 and 1 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Hepatocellular Carcinoma, Huntington Disease, Melanoma, Multiple Sclerosis, Myocardial Infarction and Parkinson's Disease.
Furthermore, this report also reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.